A Comprehensive Review of Xylazine: Synthesis, Spectral Characterization, and Detection

Sharma, Bhawna, Bhavya (2025). A Comprehensive Review of Xylazine: Synthesis, Spectral Characterization, and Detection. https://doi.org/10.70130/rcs.2025.0201005

Sharma, Bhawna, Bhavya. "A Comprehensive Review of Xylazine: Synthesis, Spectral Characterization, and Detection.". DOI: 10.70130/rcs.2025.0201005.

Sharma, Bhawna, Bhavya. "A Comprehensive Review of Xylazine: Synthesis, Spectral Characterization, and Detection.". https://doi.org/10.70130/rcs.2025.0201005.

@article{sharma2025a,
  title = {A Comprehensive Review of Xylazine: Synthesis, Spectral Characterization, and Detection},
  author = {Sharma, Bhawna and Bhavya},
  year = 2025,
  journal = {},
  volume = 02,
  number = 01,
  doi = 10.70130/rcs.2025.0201005,
  url = oai:ojs2.pubs.rsyn.org:article/148,
  language = en
}

Download .bib

TY  - JOUR
TI  - A Comprehensive Review of Xylazine: Synthesis, Spectral Characterization, and Detection
AU  - Sharma, Bhawna
AU  - Bhavya
PY  - 2025
DA  - 2025-06-28
VL  - 02
IS  - 01
DO  - 10.70130/rcs.2025.0201005
UR  - oai:ojs2.pubs.rsyn.org:article/148
AB  - Xylazine (N‑(2,6‑dimethylphenyl)‑5,6‑dihydro‑4H‑1,3‑thiazin‑2‑amine; C₁₂H₁₆N₂S; MW 220.33 g mol⁻¹) is a veterinary α₂‑adrenergic agonist widely used for sedation, analgesia, and muscle relaxation. First synthesized in 1962 (Behner et al., 1964), it now also appears as an adulterant in illicit opioids, posing public-health challenges. This review integrates insights from chemical patents, peer-reviewed studies, and public spectral databases to present: (1) classical and mechanochemical synthesis routes; (2) solid‑state polymorphism and ³⁵Cl SSNMR/DFT analyses; (3) detailed NMR, IR, Raman, and UV–Vis spectral assignments; (4) chromatographic and mass‑spectrometric detection methods; and (5) emerging field‑deployable immunoassay and electrochemical sensors. A unified framework supports regulatory compliance, forensic identification, and quality‑control laboratories.
LA  - en
ER  -

Download .ris

🤖 AI Key Takeaways & Research Insights

Automated AI Analysis

💡 Core Finding

Xylazine (N‑(2,6‑dimethylphenyl)‑5,6‑dihydro‑4H‑1,3‑thiazin‑2‑amine; C₁₂H₁₆N₂S; MW 220.33 g mol⁻¹) is a veterinary α₂‑adrenergic agonist widely used for sedation, analgesia, and muscle relaxation.

🔬 Methodology

First synthesized in 1962 (Behner et al., 1964), it now also appears as an adulterant in illicit opioids, posing public-health challenges.

🎯 Domain Impact

A unified framework supports regulatory compliance, forensic identification, and quality‑control laboratories.

Abstract

Xylazine (N‑(2,6‑dimethylphenyl)‑5,6‑dihydro‑4H‑1,3‑thiazin‑2‑amine; C₁₂H₁₆N₂S; MW 220.33 g mol⁻¹) is a veterinary α₂‑adrenergic agonist widely used for sedation, analgesia, and muscle relaxation. First synthesized in 1962 (Behner et al., 1964), it now also appears as an adulterant in illicit opioids, posing public-health challenges. This review integrates insights from chemical patents, peer-reviewed studies, and public spectral databases to present: (1) classical and mechanochemical synthesis routes; (2) solid‑state polymorphism and ³⁵Cl SSNMR/DFT analyses; (3) detailed NMR, IR, Raman, and UV–Vis spectral assignments; (4) chromatographic and mass‑spectrometric detection methods; and (5) emerging field‑deployable immunoassay and electrochemical sensors. A unified framework supports regulatory compliance, forensic identification, and quality‑control laboratories.

Xylazine spectral analysis

Full text is available at the publisher's website.

Read Full Article ↗